VIDEO: New oral IL-17 inhibitor exhibits positive data in clinical psoriasis trial

In this Healio video exclusive, Jashin J. Wu, MD, FAAD, discusses DICE Therapeutics’ phase 1 study of DC-806, a new oral interleukin-17A inhibitor, as an alternative to injectable medications in psoriasis treatment.

The study was presented at the American Academy of Dermatology Annual Meeting and showed a higher dosage of DC-806 is potentially effective in psoriasis treatment, according to Wu, a voluntary associate professor in the department of dermatology at University of Miami Miller School of Medicine.

In the study, patients received either 200 mg (n = 13) or 800 mg (n = 8) doses of DC-806 twice a day or placebo (n = 11). The higher treatment dose showed a 43.7% reduction in PASI vs. a 13.3% reduction in the placebo group; however, the lower treatment dose had a comparable PASI reduction with placebo, according to Wu.

Compared with placebo, patients on both DC-806 doses experienced a “little bit higher” rate of adverse events such as headaches, abdominal discomfort and increased risk for COVID-19, Wu said.

Reference:

• Warren RB. DC-806, an oral IL-17A inhibitor: Proof-of-concept in adults with mild to moderate psoriasis. Presented at: AAD Annual Meeting; March 17-21, 2023; New Orleans.